



SWITCHING LA CBG/RPV IN VIROLOGICALLY SUPPRESSED PLHIV. **DOES KNOWING PREVIOUS GENOTYPING REALLY MATTER? A** SUBSTUDY FROM THE RELATIVITY COHORT

Luis Buzón Martín, María Luisa Montes, María José Galindo Puerto, Miguel Torralba, Victoria García, Alfonso Cabello Úbeda, Isabel San Joaquín Conde, Luis Morano, Noemí Cabello Clotet, Patricia Martín Rico, Carmen Montero Hernández, Miguel de Zárraga Fernández, Sara De la Fuente, Ruth Calderón Hernaiz, Enrique Bernal, María Jesús Vivancos Gallego, María Antonia Sepúlveda, Roberto Pedrero-Tomé, Cristina Díez Romero, Álvaro Cecilio, Jara Llenas García, Víctor Arenas García, Carlos Armiñanzas Castillo, Antonio Jesús Sánchez Guirao, María del Mar García Navarro, Ana Cerezales Calviño, María Ángeles Garcinuño Jiménez, Eva Ferreira Pasos, Miriam Estébanez, Beatriz De la Calle Riaguas, Miguel Egido Murciano, Noemí Ramos Vicente, Marta Clavero Olmos, Juan Manuel Tiraboschi, Jesús Troya, on behalf of the RELATIVITY Project

BACKGROUND

Resistance associated mutations (RAMs) to RPV and/or INSTI,

MATERIAL AND METHODS

The relativity cohort is a nationwide Spanish cohort of PLHIV older

along with BMI>30 and HIV subtype A1/A6, increase the risk of CBG/RPV-associated virological failure. The aim of the current substudy is to compare efficacy outcomes in real life in virologically suppressed PLHIV who switched to CBG/RPV according to whether previous genotyping was available or not at the time of switching.

RESULTS

than 18 years old treated with CBG/RPV. Patients coming from CBG/RPV clinical trials are not included. 1285 cases from 37 institutions are described. Quantitative variables are compared using the U-Mann Whitney test and qualitative variables using Chi-Square and/or Fisher's exact test.

The group in which previous genotyping results were available comprised 675/1285 cases (52.5%) (see table 1). PLHIV within this group, were more frequently spanish, (74% vs 67.7%; p-value=0.012), older (46.0 years old [37.0, 56.0] vs 44.0 [37.0, 52.0]; p= 0.012) and had more psychiatric disorders (11.1% vs 7.0%; p=0.015); Besides, blips (33.0% vs 15.0%; p=0.005) and documented virological failures with any oral ART before switching (5.9% vs 3.2%; p<0.001) were more frequent in it. Time on oral ART until switch to LA CBG/RPV was significantly shorter in this group (9.0 [5.0, 12.0] vs 10.0 [6.0, 18.0] years; p-value < 0.001), as was the length of the period with undetectable viral load in plasma before switching (73.0 [37.2, 117.0] vs 96.0 [45.0, 156.0] months; p-value<0.001). The median follow-up was 7.6 [5 – 11] months Switching from DTG/RPV (26.0%vs 19.7%; p<0.001) or DRV-based regimens (6.4% vs 2.3%, p<0.001) (figure 2) was more frequent when genotyping was unavailable. There were no statistically significant differences in time of follow-up, CD4 T cell count at the time of switch and abandon rate. Surprisingly, there was trend regarding the development of virological failure favouring the group of unknown genotype (tables 1 and 2).

	Known genotype	Unknown genotype	p-value
Age (years) (median [IQR])	N = 675/1285 44.0 [37.0, 52.0]	N = 610/185 46.0 [37.0, 56.0]	0.012
Sex, n (%)		-0.0 [07.0, 00.0]	0.012
Female	89 (13.2)	94 (15.5)	0.288
Male	583 (86.8)	513 (84.5)	0.288
Nationality, n (%)	000 (00.0)	010 (04.0)	0.200
Spaniards	497 (74.0)	405 (67.7)	0.017
Migrants	175 (26.0)	193 (32.3)	0.017
CD4 nadir (cells/mm3), median [IQR]	346.0 [201.0, 500.0]	329.0 [198.5, 480.0]	0.298
HIV diagnosis viral load (copies/ml) (median [IQR])	65755.0 [19200.0, 215050.0]	49630.5 [9723.5, 156895.0]	0.005
Months from diagnosis to start of first ART (median [IQR])	2.0 [0.0, 12.0]	3.0 [1.0, 22.0]	< 0.001
AIDS, n (%)	78 (11.6)	83 (13.6)	0.322
Years of ART from treatment start to beginning of CBG/RPV (median [IQR])	9.0 [5.0, 12.0]	10.0 [6.0, 18.0]	< 0.001
Months of undetectability until start of CAB+RPV (median [IQR])	73.0 [37.2, 117.0]	96.0 [45.0, 156.0]	<0.001
Previous virological failure on any ART regimen (%)	39 (5.8)	19 (3.1)	<0.001
Which third drug was involved in the failure?, n (%)		()	
INI	9(1.3)	7(1.1)	0.702
NNRTI	9(1.3)	4 (0.7)	0.393
PIs	17 (2.5)	3 (0.5)	0.073
Notavailable	4 (0.6)	5 (0.8)	1
Number of BLIPS in the 5 years prior to CBG/RPV treatment, n (%)			
0	508 (77.0)	500 (85.0)	<0.001
1	102 (15.5)	55 (9.4)	0.281
2	23 (3.5)	19 (3.2)	0.788
3	12 (1.8)	8 (1.4)	0.52
More than 3	15 (2.3)	6 (1.0)	0.076
Baseline genotipying previous to switch, n (%)	675 (100.0)	_	
Basal genotype type B	312 (79.8)	_	
Basal genotype type A1/A2	21 (5.4)	_	
Basal genotype F/CRF	21 (5.4)	_	
Basal genotype other	37 (9.5)	_	
Not available	284		
Wild type without mutations, n (%)	451 (66.8)	_	
PLHIV harbouirng virus with RAMs to NRTI, n (%)	63 (9.3)	-	
184V	13 (1.9)	-	
Others	65 (9.6)	-	
PLHIV harbouirng virus with RAMs to NNRTI, n (%)	63 (9.3)	-	
K103N	18 (2.7)	-	
E138A	3 (0.4)	-	
Others	37 (5.5)	-	
PLHIV harbouirng virus with RAMs to INSTI, n (%)	5 (0.7)	-	
L74M/I/F	1(0.1)	-	
Т97А	2 (0.3)	-	
Others	7(1.0)		
Treatment discontinuation, n (%)	32 (4.7)	33 (5.4)	1
Days of treatment discontinuation (median [IQR])	216.0 [86.5, 279.0]	113.0 [78.0, 207.0]	0.06
Systemic adverse effects, n (%)	5 (0.7)	3 (0.5)	0.678
Related to local injection site reaction, n (%)	9(1.3)	11 (1.8)	0.17
Virological failure, n (%)	5 (0.7)	1 (0.2)	0.09
Other, n (%)	13 (1.9)	18 (3)	0.432
Type of toxicity, n (%)			
Dizziness	0 (0.0)	0 (0.0)	-
Headache	1 (20.0)	0 (0.0)	1
Dysthermia	0 (0.0)	0 (0.0)	-
Fever	1 (20.0)	2 (66.7)	1
Nausea	0 (0.0)	0 (0.0)	-
Others	3 (60.0)	1 (33.3)	1




Figure 1: Percentage of PLHIV with VL<50 copies/mL in both subgroups throughout the different follow up periods

Known genotype

Unknown genotype

Table 1. Basal characteristics of both groups of the cohort according to genotype availability

	1	2*	3	4**	5	6***
Sex	Male	Male	Male	Male	Female	Male
Age (years)	49	45	40	50	52	49
Body Mass Index (Kg/m ²)	22.5	29.3	24.3	33.9	36.3	27.5
Previous treatment	BIC/FTC/TAF	DTG/3TC	DTG/3TC	DTG/3TC	DTG/RPV	BIC/FTC/TAF
Month of discontinuation	7	7	9	9	1	9
Viral Load at discontinuation	3140	44000	289	128000	362	217
Previous mutations	Wild type without mutations	-	Wild type without mutations	INSTI: Q148K; Q148R; E157Q; NNRTI: G140S; L74M/I/F; T97A	184V; K103N	Wild type without mutations
New resistance mutations	No	INSTI: E138K, Q148R, L74LM and NNRTI: K103N, Y188L	No	INSTI: L100I; K103N	No	INSTI: Y143YS; Q148R
Oral ART after VF	DTG/3TC	DRVc/FTC/TAF	BIC/FTC/TAF	DRVc/FTC/TAF	DRVc/FTC/TAF	DRVc/FTC/TAF
VLsupression	Yes	No	Yes	Yes	Yes	Yes




Figure 2: Oral ART previous to switch in both groups

Table 2. Description of cases with confirmed virologic failure.*Screening failure. Previous VF with probable RAMs against INSTI unnoticed; **Patient with baseline mutations not known at the moment of switch *** Patient undetectable at the time of switch to oral ART. Two previous viral loads>200, last 217. In spite of it, resistances to INSTI were detected.

<u>CONCLUSIONS</u>

Our results suggest that unavailability of previous genotyping doesn't seem to increase the risk of virological failure in virologically suppressed PLHIV who switch to LA CBG/RPV. These seems to line up with the results of the CARES study. Nevertheless, a longer follow up is required to reach solid conclusions.

